Previous studies have shown that vascular endothelial growth factor (VEGF) promotes progression in epithelial ovarian cancer and that blockade of VEGF inhibits growth of this tumor and metastasis. Bevacizumab is a humanized anti-VEGF monoclonal antibody that has single-agent activity in women with recurrent ovarian tumors. This multinational double-blind placebo-controlled trial was designed to evaluate the addition of bevacizumab to standard front-line ovarian cancer therapy in patients with stage III or IV epithelial ovarian cancer. All eligible patients with previously untreated incompletely resectable stage III or any stage IV epithelial ovarian cancer after maximal debulking surgery were randomized to 1 of 3 groups (control, bevacizumab-initiation treatment, and bevacizumab-throughout treatment). Each of the 3 regimens was composed of 22 three-week cycles, with intravenous infusions during first 6 cycles of both carboplatin at an area under the curve of 6 and paclitaxel at a dose of 175 mg/m of body-surface area (carboplatin and paclitaxel (CP) therapy). The control group received CP therapy with placebo added in cycles 2 through 22; bevacizumab-initiation group received CP therapy with addition of bevacizumab (15 mg/kg body weight) in cycles 2 through 6 and placebo in cycles 7 through 22; and Polycystic Ovary Syndrome 289